Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426222 | 1.00 | MPI (0.34) | MPIAKR1B1 | |
| SCHEMBL1131549 | 1.00 | MPI (0.34) | MPIAKR1B1 | |
| SCHEMBL11077622 | 1.00 | MPI (0.34) | MPIAKR1B1 | |
| SCHEMBL11076376 | 1.00 | MPI (0.34) | MPIAKR1B1 | |
| SCHEMBL27994793 | 0.92 | MPI (0.35) | MPIAKR1B1 | |
| SCHEMBL4278103 | 0.92 | MPI (0.35) | MPIAKR1B1 | |
| Demannose SCHEMBL11074350 | 0.91 | LMNA (0.46) | MPIAKR1B1 | |
| Galactose SCHEMBL9515293 | 0.91 | LMNA (0.46) | MPIAKR1B1 | |
| SCHEMBL7148720 | 0.81 | MPI (0.32) | MPI | |
| SCHEMBL23072256 | 0.78 | AKR1B1 (0.37) | MPIAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552176-B2 | Glycosylated chlorambucil analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-10-08 | — | — | US | claimed |
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | INTERSTITIAL THERAPEUTICS (CH) | 2009-12-31 | — | — | US | claimed |
| EP-1789030-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| EP-1789107-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| WO-2006024488-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024490-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024491-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024492-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| EP-0130054-B1 | NOVEL FRUCTOSYLTRANSFERASE, PROCESS FOR THE PREPARATION OF FRUCTOSYL DISACCHARIDES, AND A NOVEL HALOSUCROSE | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1990-03-07 | — | — | EP | claimed |
| US-4617269-A | WITH TRANSFERASE ENZYMES DERIVED FROM BACILLUS | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1986-10-14 | — | — | US | claimed |
| EP-0130054-A2 | Novel Fructosyltransferase, process for the preparation of Fructosyl disaccharides, and a novel halosucrose | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1985-01-02 | — | — | EP | claimed |
| US-4225590-A | Male fertility-inhibiting compositions of 6-chlorodeoxy-saccharides | TATE & LYLE LIMITED (GB) | 1980-09-30 | — | — | US | claimed |
| JP-10042883-A | — | — | None | — | — | JP | disclosed |
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | INTERSTITIAL THERAPEUTICS (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20070292478-A1 | Medical Implant Provided with Inhibitors of Atp Synthesis | INTERSTITIAL THERAPEUTICS (CH) | 2007-12-20 | — | — | US | disclosed |
| EP-1789107-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-4226749-A | POLYETHYLENIMINE, METHACRYLIC ACID INTERPOLYMER | MANUFACTURE DE PRODUITS CHIMIQUES PROTEX S.A. (FR) | 1980-10-07 | — | — | US | disclosed |
| US-4225590-A | Male fertility-inhibiting compositions of 6-chlorodeoxy-saccharides | TATE & LYLE LIMITED (GB) | 1980-09-30 | — | — | US | disclosed |
| EP-0015652-A1 | 6-Chloro-6-deoxy-D-hexitols, their esters, their preparation, fertility control compositions containing them and their use in a contraceptive method | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1980-09-17 | — | — | EP | disclosed |
| EP-0015757-A1 | Process for the preparation of chlorodeoxysugars | TATE & LYLE PATENT HOLDINGS LIMITED (BM) | 1980-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | ATP5ME, ATP5F1A, ATP5MG | MPI 193/4885AKR1B1 2102/4885 |
| US-20070292478-A1 | Medical Implant Provided with Inhibitors of Atp Synthesis | ATP5F1A, ATP5ME, ATP5MG | MPI 365/4885AKR1B1 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.